REGN

Regeneron Pharmaceuticals
D

REGN

538.11
USD
-8.77
(-1.60%)
مغلق
حجم التداول
32,111
الربح لكل سهم
35
العائد الربحي
0.32
P/E
14
حجم السوق
58,097,313,591
أصول ذات صلة
AMGN
AMGN
-5.47
(-1.83%)
293.05 USD
BIIB
BIIB
-1.870
(-1.42%)
130.130 USD
BMY
BMY
-0.590
(-1.25%)
46.490 USD
GILD
GILD
1.040
(0.94%)
111.800 USD
INCY
INCY
-1.190
(-1.74%)
67.280 USD
MRK
MRK
-0.110
(-0.14%)
80.900 USD
PFE
PFE
-0.200
(-0.79%)
25.240 USD
VRTX
VRTX
0.38
(0.08%)
459.65 USD
المزيد
الأخبار المقالات

العنوان: Regeneron Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).